Tenofovir Disoproxil Fumarate (TDF, CAS 202138-50-9)
Meta Descriptions Tenofovir Disoproxil Fumarate (TDF, CAS 202138-50-9) is a nucleotide reverse transcriptase inhibitor (NRTI) used for the treatment of HIV-1/2 infections and chronic hepatitis B. As a prodrug, it is hydrolyzed to tenofovir, which inhibits viral DNA polymerase by competing with natural deoxyribonucleotides, thereby terminating viral replication. Approved by the WHO as an essential medicine, TDF is widely prescribed in combination therapies such as Truvada® (TDF + emtricitabine) for HIV pre-exposure prophylaxis (PrEP). 替诺福韦二吡呋酯（TDF，CAS 202138-50-9）是一种核苷类逆转录酶抑制剂（NRTI），用于治疗HIV-1/2感染和慢性乙型肝炎。作为前药，其在体内水解为替诺福韦，通过竞争性抑制病毒DNA聚合酶阻断病毒复制。该药物被世界卫生组织列为基本药物，常与恩曲他滨联用（如Truvada®）用于HIV暴露前预防（PrEP）。 1. Basic Information 2. Pharmacological Mechanism 3. Clinical Applications 4. Dosage and Administration 5. Adverse Effects and Precautions 6. Research and Developments 7. Market and Regulatory Status